| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5846702 | Toxicology and Applied Pharmacology | 2012 | 9 Pages |
Abstract
⺠Nedaplatin at a pharmacological dose inhibits TrxR in cancer cells but not in kidney. ⺠The nedaplatin-treated cancer cells exhibit adaptive response. ⺠Buthionine sulfoximine inhibits glutathione in both cancer cells and kidney. ⺠Buthionine sulfoximine counteracts the adaptive response to the nedaplatin treatment. ⺠Buthionine sulfoximine does not aggravate renal toxicity of the nedaplatin treatment.
Keywords
CDNBNDPNedaplatinH22RNRPLTASK1BSOi.p.DTNBRBCGPXNADPHGSHGSTRed blood cells1-chloro-2,4-dinitrobenzeneBSAbovine serum albuminbuthionine sulfoximineSCLCBUNIntraperitoneallyRibonucleotide reductaseNSCLCLymphocytesurea nitrogennicotinamide-adenine dinucleotide phosphateHemoglobinHgbPlateletsnon-small-cell lung carcinomaSmall cell lung carcinomareduced glutathionecreatinineGranulocytesglutathione S-transferaseglutathione reductaseglutathione peroxidase
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Yijun Wang, Hongjuan Lu, Dongxu Wang, Shengrong Li, Kang Sun, Xiaochun Wan, Ethan Will Taylor, Jinsong Zhang,